Screening Dyrk1A inhibitors by MALDI-QqQ mass spectrometry: Systematic comparison to established radiometric, luminescence, and LC-UV-MS assays

Analytical and Bioanalytical Chemistry

Volumn 406, Issue 12, 2014, Pages 2841-2852

  Gode, David ^a   Schmitt, Christian ^a   Engel, Matthias ^a   Volmer, Dietrich A ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

Enzyme inhibitors; Kinase assay; Phosphopeptide assay .MALDI triple quadrupole

Indexed keywords

CONTRAST MEDIA; DIAGNOSIS; ENZYMES; LIQUID CHROMATOGRAPHY; LUMINESCENCE; MASS SPECTROMETRY; PEPTIDES; PHOSPHORYLATION; RADIOMETRY; SUGAR SUBSTITUTES;

ENZYME INHIBITORS; ENZYME-CATALYZED REACTIONS; KINASE ASSAYS; MATRIX ASSISTED LASER DESORPTION/IONIZATION; MULTIPLE-REACTION MONITORING MODES; PHOSPHORYLATED PEPTIDES; TRIPLE QUADRUPOLE; ULTRA VIOLET DETECTION;

ASSAYS;

DYRK KINASE; PEPTIDE; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE;

ANTAGONISTS AND INHIBITORS; CHEMISTRY; COMPARATIVE STUDY; DEVICES; DRUG SCREENING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LUMINESCENCE; MASS SPECTROMETRY; PROCEDURES; RADIOMETRY;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG EVALUATION, PRECLINICAL; HUMANS; LUMINESCENCE; PEPTIDES; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; RADIOMETRY; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 84904381452     PISSN: 16182642     EISSN: 16182650     Source Type: Journal    
DOI: 10.1007/s00216-014-7703-1     Document Type: Article

References (58)

1. Traxler P, Furet P (1999) Strategies toward the design of novel and selective protein tyrosine kinase inhibitors. Pharmacol Ther 82:195-206. doi:10.1016/S0163-7258(98)00044-8
2. Chico LK, Van Eldik LJ, Watterson DM (2009) Targeting protein kinases in central nervous system disorders. Nat Rev Drug Discov 8: 892-909. doi:10.1038/nrd2999
3. Lahiry P, Torkamani A, Schork NJ, Hegele RA (2010) Kinase mutations in human disease: interpreting genotype-phenotype relationships. Nat Rev Genet 11:60-74. doi:10.1038/nrg2707
4. Becker W, Weber Y, Wetzel K, Eirmbter K, Tejedor FJ, Joost HG (1998) Sequence characteristics, subcellular localization, and substrate specificity of DYRK-related kinases, a novel family of dual specificity protein kinases. J Biol Chem 273:25893-25902. doi:10.1074/jbc.273.40.25893
5. Himpel S, Panzer P, Eirmbter K, Czajkowska H, Sayed M, Packman LC, Blundell T, Kentrup H, Grötzinger J, Joost HG, BeckerW(2001) Identification of the autophosphorylation sites and characterization of their effects in the protein kinase DYRK1A. Biochem J 359:497-505
6. Lochhead PA, Sibbet G, Morrice N, Cleghon V (2005) Activationloop autophosphorylation is mediated by a novel transitional intermediate formofDYRKs. Cell 121:925-936. doi:10.1016/j.cell.2005.03.034
7. Becker W, Joost HG (1999) Structural and functional characteristics of Dyrk, a novel subfamily of protein kinases with dual specificity. Prog Nucleic Acid Res Mol Biol 62:1-17. doi:10.1016/S0079-6603(08)60503-6
8. Woods YL, Cohen P, BeckerW, Jakes R, GoedertM,Wang X, Proud CG (2001) The kinase DYRK phosphorylates protein-synthesis initiation factor eIF2Bepsilon at Ser539 and the microtubule-Associated protein tau at Thr212: potential role for DYRK as a glycogen synthase kinase 3-priming kinase. Biochem J 355:609-615
9. DowjatWK, Adayev T, Kuchna I, Nowicki K, Palminiello S, Hwang Y-W, Wegiel J (2007) Trisomy-driven overexpression of DYRK1A kinase in the brain of subjects with Down syndrome. Neurosci Lett 413:77-81. doi:10.1016/j.neulet.2006. 11.026
10. Guimerá J, Casas C, Pucharcòs C, Solans A, Doménech A, Planas AM, Ashley J, Lovett M, Estivill X, Pritchard MA (1996) A human homologue of Drosophila minibrain (MNB) is expressed in the neuronal regions affected in Down syndrome and maps to the critical region. Hum Mol Genet 5:1305-1310. doi:10.1093/hmg/5.9.1305
11. Liu F, Liang Z, Wegiel J, Hwang Y-W, Iqbal K, Grundke-Iqbal I, Ramakrishna N, Gong C-X (2008) Overexpression of Dyrk1A contributes to neurofibrillary degeneration in Down syndrome. FASEB J 22:3224-3233. doi:10.1096/fj.07-104539
12. Johnson GVW, StoothoffWH (2004) Tau phosphorylation in neuronal cell function and dysfunction. J Cell Sci 117:5721-5729. doi:10.1242/jcs.01558
13. Steinhilb ML, Dias-Santagata D, Fulga TA, Felch DL, Feany MB (2007) Tau phosphorylation sites work in concert to promote neurotoxicity in vivo.Mol Biol Cell 18:5060-5068. doi:10.1091/mbc.E07-04-0327
14. Wegiel J, Dowjat WK, Kaczmarski W, Kuchna I, Nowicki K, Frackowiak J, Mazur Kolecka B, Wegiel J, Silverman WP, Reisberg B, Deleon M, Wisniewski T, Gong C-X, Liu F, Adayev T, Chen-Hwang M-C, Hwang Y-W (2008) The role of overexpressed DYRK1A protein in the early onset of neurofibrillary degeneration in Down syndrome. Acta Neuropathol 116:391-407. doi:10.1007/ s00401-008-0419-6
15. Wegiel J, Gong C-X, Hwang Y-W (2011) The role of DYRK1A in neurodegenerative diseases. FEBS J 278:236-245. doi:10.1111/j.1742-4658.2010. 07955.x
16. Von Ahsen O, Bömer U (2005) High-throughput screening for kinase inhibitors. Chembiochem 6:481-490. doi:10.1002/cbic.200400211
17. Macarron R, Banks MN, Bojanic D, Burns DJ, Cirovic DA, Garyantes T, Green DVS, Hertzberg RP, Janzen WP, Paslay JW, Schopfer U, Sittampalam GS (2011) Impact of high-throughput screening in biomedical research. Nat Rev Drug Discov 10:188-195. doi:10.1038/nrd3368
18. Rathore R, Pribil P, Corr JJ, Seibel WL, Evdokimov A, Greis KD (2010) Multiplex enzyme assays and inhibitor screening by mass spectrometry. J Biomol Screen 15:1001-1007. doi:10.1177/1087057110363824
19. Nelson SL (2008) Academic HTS: diverse portraits. Drug Discov Today Technol 5:e29-e33. doi:10.1016/j.ddtec.2009.01.001
20. Greis KD (2007) Mass spectrometry for enzyme assays and inhibitor screening: an emerging application in pharmaceutical research. Mass Spectrom Rev 26:324-339. doi:10.1002/mas.20127
21. Roddy TP, Horvath CR, Stout SJ, Kenney KL, Ho P-I, Zhang J-H, Vickers C, Kaushik V, Hubbard B, Wang YK (2007) Mass spectrometric techniques for label-free high-throughput screening in drug discovery. Anal Chem 79:8207-8213. doi:10.1021/ac062421q
22. Deng G, Sanyal G (2006) Applications of mass spectrometry in early stages of target based drug discovery. J Pharm Biomed Anal 40:528-538. doi:10.1016/j.jpba.2005.08.038
23. Xu Z, Yao S, Wei Y, Zhou J, Zhang L, Wang C, Guo Y (2008) Monitoring enzyme reaction and screening of inhibitors of acetylcholinesterase by quantitative matrix-Assisted laser desorption/ ionization Fourier transform mass spectrometry. J Am Soc Mass Spectrom 19:1849-1855. doi:10.1016/j.jasms.2008.07. 025
24. Cai T, Zhang L,Wang H, Zhang J, Guo Y (2011) Assisted inhibition effect of acetylcholinesterase with n-octylphosphonic acid and application in high sensitive detection of organophosphorous pesticides by matrix-Assisted laser desorption/ionization Fourier transform mass spectrometry. Anal Chim Acta 706:291-296. doi:10.1016/j.aca.2011.08.035
25. Hooff GP, van Kampen JJA, Meesters RJW, van Belkum A, Goessens WHF, Luider TM (2012) Characterization of β-lactamase enzyme activity in bacterial lysates using MALDI-mass spectrometry. J Proteome Res 11:79-84. doi:10.1021/pr200858r
26. Xu Z, Wang H-Y, Huang S-X, Wei Y-L, Yao S-J, Guo Y-L (2010) Determination of beta-lactamase residues in milk using matrixassisted laser desorption/ionization Fourier transform mass spectrometry. Anal Chem 82:2113-2118. doi:10.1021/ac9019945
27. Djung JF, Mears RJ, Montalbetti CAGN, Coulter TS, Golebiowski A, Carr AN, Barker O, Greis KD, Zhou S, Dolan E, Davis GF (2011) The synthesis and evaluation of indolylureas as PKC inhibitors. Bioorg Med Chem 19:2742-2750. doi:10.1016/j.bmc.2011.02.036
28. Greis KD, Zhou S, Burt TM, Carr AN, Dolan E, Easwaran V, Evdokimov A, Kawamoto R, Roesgen J, Davis GF (2006) MALDI-TOF MS as a label-free approach to rapid inhibitor screening. J Am Soc Mass Spectrom 17:815-822. doi:10.1016/j.jasms.2006.02.019
29. Kondo N, Nishimura S (2009) MALDI-TOF mass-spectrometrybased versatile method for the characterization of protein kinases. Chemistry 15:1413-1421. doi:10.1002/chem.200801650
30. Bungert D, Heinzle E, Tholey A (2004) Quantitative matrix-Assisted laser desorption/ionization mass spectrometry for the determination of enzyme activities. Anal Biochem 326:167-175. doi:10.1016/j.ab.2003.11.013
31. Rathore R, Corr JJ, Lebre DT, Seibel WL, Greis KD (2009) Extending matrix-Assisted laser desorption/ionization triple quadrupole mass spectrometry enzyme screening assays to targets with small molecule substrates. Rapid Commun Mass Spectrom 23: 3293-3300. doi:10.1002/rcm.4248
32. Matsumoto H, Kahn ES, Komori N (1998) Nonradioactive phosphopeptide assay by matrix-Assisted laser desorption ionization time-offlight mass spectrometry: application to calcium/calmodulindependent protein kinase II. Anal Biochem 260:188-194. doi:10.1006/abio.1998.2691
33. Craig AG, Hoeger CA, Miller CL, Goedken T, Rivier JE, Fischer WH (1994) Monitoring protein kinase and phosphatase reactions with matrix-Assisted laser desorption/ionization mass spectrometry and capillary zone electrophoresis: comparison of the detection efficiency of peptide-phosphopeptide mixtures. BiolMass Spectrom 23: 519-528. doi:10.1002/bms.1200230810
34. Chen J, Qi Y, Zhao R, Zhou GW, Zhao ZJ (2001) Assay of protein tyrosine phosphatases by using matrix-Assisted laser desorption ionization time-of-flight mass spectrometry. Anal Biochem 292:51-58. doi:10.1006/abio.2001.5071
35. Steen H, Jebanathirajah JA, Rush J,Morrice N, KirschnerMW(2006) Phosphorylation analysis by mass spectrometry: myths, facts, and the consequences for qualitative and quantitative measurements. Mol Cell Proteomics 5:172-181. doi:10.1074/mcp.M500135-MCP200
36. Tsuchiya A, Asai D, Kang J-H, Mori T, Niidome T, Katayama Y (2012) Correlation between phosphorylation ratios bymatrix-Assisted laser desorption/ionization time-of-flight mass spectrometry analysis and radioactivities by radioactive assay. Anal Biochem 421:773-775. doi:10.1016/j.ab.2011.08.035
37. Parker L, Engel-Hall A, Drew K, Steinhardt G, Helseth DL, Jabon D, McMurry T, Angulo DS, Kron SJ (2008) Investigating quantitation of phosphorylation using MALDI-TOF mass spectrometry. J Mass Spectrom 43:518-527. doi:10.1002/jms.1342
38. Rathore R, Corr JJ, Scott G, Vollmerhaus P, Greis KD (2008) Development of an inhibitor screening platform via mass spectrometry. J Biomol Screen 13:1007-1013. doi:10.1177/1087057108326143
39. Tuytten R, Lemiére F,Witters E, Van DongenW, Slegers H, Newton RP, Van Onckelen H, Esmans EL (2006) Stainless steel electrospray probe: a dead end for phosphorylated organic compounds? J Chromatogr A 1104:209-221. doi:10.1016/j.chroma.2005.12.004
40. Liu S, Zhang C, Campbell JL, Zhang H, Yeung KK-C, Han VKM, Lajoie GA (2005) Formation of phosphopeptide-metal ion complexes in liquid chromatography/electrospray mass spectrometry and their influence on phosphopeptide detection. Rapid Commun Mass Spectrom 19:2747-2756. doi:10.1002/rcm.2105
41. Gropengiesser J, Varadarajan BT, Stephanowitz H, Krause E (2009) The relative influence of phosphorylation andmethylation on responsiveness of peptides to MALDI and ESI mass spectrometry. J Mass Spectrom 44:821-831. doi:10.1002/jms.1581
42. Schmitt C, Kail D, Mariano M, Empting M, Weber N, Paul T, Hartmann RW, Engel M (2014) Design and synthesis of a library of lead-like 2,4-bisheterocyclic substituted thiophenes as selective Dyrk/Clk inhibitors. PLoS One. doi:10.1371/journal.pone.0087851
43. Sleno L, Volmer DA (2005) Some fundamental and technical aspects of the quantitative analysis of pharmaceutical drugs by matrixassisted laser desorption/ionization mass spectrometry. Rapid Commun Mass Spectrom 19:1928-1936. doi:10.1002/rcm.2006
44. Sleno L, Volmer DA (2006) Assessing the properties of internal standards for quantitative matrix-Assisted laser desorption/ionization mass spectrometry of small molecules. Rapid Commun Mass Spectrom 20:1517-1524. doi:10.1002/rcm.2498
45. Sleno L, Volmer DA (2005) Toxin screening in phytoplankton: detection and quantitation using MALDI triple quadrupole mass spectrometry. Anal Chem 77:1509-1517. doi:10.1021/ac0486600
46. Kapkova P, Lattova E, Perreault H (2006) Nonretentive solid-phase extraction of phosphorylated peptides from complex peptide mixtures for detection bymatrix-Assisted laser desorption/ionizationmass spectrometry. Anal Chem 78:7027-7033. doi:10.1021/ac060485v
47. Zhou L-H, Kang G-Y, Kim KP (2009) A binary matrix for improved detection of phosphopeptides in matrix-Assisted laser desorption/ ionization mass spectrometry. Rapid Commun Mass Spectrom 23: 2264-72. doi:10.1002/rcm.4139
48. Herberich E, Sikorski J, Hothorn T (2010) A robust procedure for comparing multiple means under heteroscedasticity in unbalanced designs. PLoS One 5:e9788. doi:10.1371/journal.pone. 0009788
49. Glickman J (2004) Assay Development for Protein Kinase Enzymes. 1-19
50. Göckler N, Jofre G, Papadopoulos C, Soppa U, Tejedor FJ, Becker W, Gockler N (2009) Harmine specifically inhibits protein kinase DYRK1A and interferes with neurite formation. FEBS J 276:6324-6337. doi:10.1111/j.1742- 4658.2009.07346.x
51. Gehrig PM, Roschitzki B, Rutishauser D, Reiland S, Schlapbach R (2009) Phosphorylated serine and threonine residues promote sitespecific fragmentation of singly charged, arginine-containing peptide ions. Rapid Commun Mass Spectrom 23:1435-1445. doi:10.1002/ rcm.4019
52. Rožman M (2011) Modelling of the gas-phase phosphate group loss and rearrangement in phosphorylated peptides. J Mass Spectrom 46: 949-955. doi:10.1002/jms.1974
53. Boersema PJ, Mohammed S, Heck AJR (2009) Phosphopeptide fragmentation and analysis by mass spectrometry. J Mass Spectrom 44:861-878. doi:10.1002/jms.1599
54. Gratz A, Götz C, Jose J (2010) A CE-based assay for human protein kinase CK2 activity measurement and inhibitor screening. Electrophoresis 31:634-640. doi:10.1002/elps.200900514
55. Zhang J-H (1999) A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 4:67-73. doi:10.1177/108705719900400206
56. Tanega C, Shen M, Mott BT, Thomas CJ, MacArthur R, Inglese J, Auld DS (2009) Comparison of bioluminescent kinase assays using substrate depletion and product formation. Assay Drug Dev Technol 7:606-614. doi:10.1089/adt.2009.0230
57. Hastie CJ,McLauchlan HJ, Cohen P (2006) Assay of protein kinases using radiolabeled ATP: a protocol. Nat Protoc 1:968-971. doi:10.1038/nprot.2006.149
58. Hu L, Jiang G, Xu S, Pan C, Zou H (2006) Monitoring enzyme reaction and screening enzyme inhibitor based on MALDI-TOF-MS platform with a matrix of oxidized carbon nanotubes. J Am SocMass Spectrom 17:1616-1619. doi:10.1016/j.jasms.2006.07.005